Large clinical trials have not identified bone loss as a significant adverse effect, though the weight loss these medications produce may indirectly affect bone density in some individuals
If the strength of the medication changes because of exposure to improper temperatures, it can mess with how the body responds
Weight loss treatments are evolving rapidly, with Mazdutide and Tirzepatide emerging as promising options for the future
Mounjaro (tirzepatide) label
Many preclinical studies have demonstrated that the expression of key enzymes for GSH synthesis (GCL, SLC7A11, GS) and GSSG reduction-related enzymes (G6PD, NADPH, and GR) is downregulated in myocardium exposed to pathological factors [40, 43,44,45,46,47,48,49,50]
Step four: treatment selection